{
    "title": "112_hr6502",
    "content": "The Act titled \"Life-Threatening Diseases Compassion through Combination Therapy Act of 2012\" promotes the development of combinations of investigational new drugs for serious diseases by providing marketing exclusivity and priority review for significant drug combinations. The Act \"Life-Threatening Diseases Compassion through Combination Therapy Act of 2012\" allows the Secretary to designate a combination of drugs as significant if they have the potential to advance treatment for serious diseases and meet specific criteria for codevelopment outlined by the FDA. The Secretary can designate a combination of unapproved drugs for codevelopment to encourage the advancement of treatment for serious diseases. Requests for designation must be made by the manufacturer or sponsor of the drugs. The Secretary can determine if a combination of 2 or more drugs is significant within 30 days of a request. If the combination meets requirements, it will be designated as a significant drug combination. The Secretary will designate a drug combination as significant if it meets requirements, otherwise, it will not be designated as significant. The Secretary will designate drug combinations as significant based on specific criteria. A request for designation must be made alongside or after submitting an application for drug investigation. A list of significant drug combinations will be developed and published within 180 days of the Act's enactment. The Secretary will develop and publish an initial list of significant drug combinations on the FDA website. This list will be updated annually to include new combinations and exclude those no longer meeting the criteria. Market exclusivity may be extended for drugs designated as significant combinations before approval. The FDA will publish a list of significant drug combinations on their website, updated annually. Market exclusivity can be extended by 6 months for drugs in designated combinations before approval, with limitations on supplements to the original application. The FDA allows for a 6-month extension of market exclusivity for drugs in designated significant drug combinations, either for the original application or subsequent applications with specific changes or modifications. The FDA grants a 6-month priority review for drugs in significant drug combinations, ensuring action on applications within 6 months. \"Significantly advance treatment\" refers to drugs treating life-threatening conditions with no existing therapy or showing improved effects on serious outcomes. The FDA grants a 6-month priority review for drugs in significant drug combinations, ensuring action on applications within 6 months. This applies to drugs treating life-threatening conditions with no existing therapy or showing improved effects on serious outcomes. SEC. 3. CODEVELOPMENT TASK FORCE. Establishment of an interagency task force by the Secretary of Health and Human Services within 6 months of this Act to promote codevelopment of drugs in significant combinations. Task force membership includes experts in research and drug development for serious diseases. Duties include recommending a list of significant drug combinations for designation under the Federal Food, Drug, and Cosmetic Act. Public input on the list is required. The interagency task force established by the Secretary of Health and Human Services will recommend significant drug combinations for designation under the Federal Food, Drug, and Cosmetic Act. The list will be made publicly available for comments, revised based on feedback, and updated annually. The interagency task force will recommend significant drug combinations for designation under the Federal Food, Drug, and Cosmetic Act. A policy report will be submitted annually to identify challenges and opportunities for codevelopment of drugs in significant combinations, along with recommendations for policy changes to support this. The interagency task force will recommend significant drug combinations for designation under the Federal Food, Drug, and Cosmetic Act. Before submitting the report, the task force will make a draft publicly available for public comment. The term \"significant drug combination\" refers to a combination of drugs that offer potential advancements in treating serious diseases. The interagency task force will recommend significant drug combinations for designation under the Federal Food, Drug, and Cosmetic Act. These combinations must offer potential advancements in treating serious diseases and meet specific criteria for codevelopment of drug combinations. The combinations should include at least 2 drugs that are not approved under certain acts. The Secretary of Health and Human Services will conduct a study on the impact of exclusivity extensions on significant drug combinations. Interim findings will be shared with a task force and the public, with an opportunity for comments. Final findings will be submitted to Congress within 5 years."
}